Boehringer In­gel­heim-backed Aba­los toss­es hat in­to packed on­colyt­ic virus ring

Are­navirus­es. They’re small, they’re packed with tiny stolen ri­bo­somes that re­sem­ble grains of sand, they’re re­spon­si­ble for 300,000 to 500,000 hu­man in­fec­tions in West Africa each year, and, if a new Ger­man biotech has their way, they are go­ing to one day treat tu­mors.

Aba­los Ther­a­peu­tics launched to­day with $12 mil­lion in fund­ing to de­vel­op are­navirus­es it hopes can be used in im­munother­a­py for can­cer. The fund­ing was co-led by Boehringer In­gel­heim Ven­ture Fund (BIVF) and Gru­en­der­fonds Ruhr, with par­tic­i­pa­tion from NRW.BANK and High-Tech Gru­en­der­fonds (HT­GF).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.